Nomura Securities Starts Valeant Pharmaceuticals (VRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Valeant Pharmaceuticals (VRX) Subpoena 'Far from Certain', UBS Says; Sees Bounce Back in Stock
September 29, 2015 8:46 AM EDTUBS analyst Marc Goodman reiterated a Buy rating and $285 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's sell-off amid news Democratic members of the House Committee on Oversight and Govt Reform sent a letter requesting Chairman Jason Chaffetz (Republican) to subpoena Valeant to turn over documents related to price increases for these products.
Goodman notes that, importantly,... More
Fear and Uncertainty Creates Buying Opportunity in Valeant (VRX) - BMO Capital
September 29, 2015 7:50 AM EDTBMO Capital analyst Alex Arfaei has come out to defend Valeant Pharmaceuticals (NYSE: VRX) which has been under pressure amid the political backlash over soaring drug prices, including yesterday's request for a subpoena from all 18 Democratic... More
